Alzheimer’s Drug Discovery Foundation (ADDF) provided support for the development of novel tools for drug discovery applications, including cellular models of disease and biosensors that allow for sensitive detection of the interaction between two proteins involved in Alzheimer’s disease, CDK5 and p25.
Kate Johnston, chief scientific officer of Cellumen, said: “Cellumen is grateful for the support of the ADDF and for the opportunity to develop products and applications for important targets that have been difficult to screen with traditional drug discovery methodology.”